nach oben

Current Oncology Reports

Erschienen in:

01.01.2015 | Gastrointestinal Cancers (B Czito, Section Editor)

Update on Treatment of Liver Metastases: Focus on Ablation Therapies

verfasst von: Jeffrey Meyer, Seth Toomay

Erschienen in: Current Oncology Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

There is substantial and growing interest in the use of local therapies to treat patients with metastatic cancer, especially those deemed to have “oligometastatic” disease. Much of the literature to date consists of reports on metastasectomy for liver and lung metastases. Non-surgical minimally or non-invasive treatments including thermal ablation, irreversible electroporation, and high-dose radiation therapy (stereotactic ablative radiation therapy) can also be used in the treatment of primary and secondary tumors, including in the treatment of liver metastases. In this review, we discuss the rationale for using these ablative treatments in the treatment of liver metastases including similarities and differences between them.

Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203.PubMedCrossRef

Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125–35.PubMedCrossRef

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.PubMed

Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82.PubMed

5.••

Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state—separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–57. A very important overview of controversies regarding the concept of oligometastatic disease. Discusses important issues inherent in clinical trials addressing treatment of oligometastatic disease.PubMedCrossRef

Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol. 2014;31(2):180–6.PubMedCrossRef

Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.PubMedCrossRef

Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25 Suppl 1:S69–83.PubMedCrossRef

Ng KK, Lam CM, Poon RT, Shek TW, Ho DW, Fan ST. Safety limit of large-volume hepatic radiofrequency ablation in a rat model. Arch Sug. 2006;141(3):252–8.CrossRef

10.

Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.PubMedCentralPubMedCrossRef

11.

Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14(1):1267–74.PubMedCrossRef

12.

Levit E, Bruners P, Gunther RW, Mahnken AH. Bile aspiration and hydrodissection to prevent complications in hepatic RFA close to the gallbladder. Acta Radiol. 2012;53(9):1045–8.PubMedCrossRef

13.

Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd 3rd GD, et al. American society of clinical oncology 2009 clinical evidence review of radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508.PubMedCrossRef

14.

Doyle MB, Chapman WC. Radiofrequency ablation for resectable colorectal hepatic metastases: is it time for a randomized controlled trial? Ann Surg. 2010;251(5):804–6.PubMedCrossRef

15.

Chen M-S, Li J-Q, Zheng Y, Guo R-P, Liang H-H, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321–8.PubMedCentralPubMedCrossRef

16.

Groeschl RT, Pilgrim CH, Hanna EM, Simo KA, Swan RZ, Sindram D, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200.PubMedCrossRef

17.

Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.PubMedCrossRef

18.

Lee EW, Wong D, Tafti BA, Prieto V, Totonchy M, Hilton J, et al. Irreversible electroporation in eradication of rabbit VX2 liver tumor. J Vasc Interv Radiol. 2012;23(6):833–40.PubMedCrossRef

19.

Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat. 2007;6(1):37–48.PubMedCrossRef

20.

Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011;6(4):e18831.PubMedCentralPubMedCrossRef

21.

Lee EW, Chen C, Prieto EV, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010;255(2):426–33.PubMedCrossRef

22.

Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg. 2010;110(50):1305–9.PubMedCrossRef

23.

Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–21.PubMedCrossRef

24.

Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13(3):168–73.

25.••

Silk M, Wimmer T, Lee KS, Srimathveeravalli G, Brown KT, Kingham PT, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–8. Early clinical results of irreversible electroporation in the treatment of liver tumors located near critical structures.PubMedCrossRef

26.••

Cannon R, Ellis S, Hayes D, Narayanan G, Martin 2nd RC. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9. Early clinical results of irreversible electroporation for tumors near critical structures.PubMedCrossRef

27.

Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100.PubMedCrossRef

28.

Reed Jr GB. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol. 1966;48(4):597–611.PubMedCentralPubMed

29.

Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014;32(26):2847–54.PubMedCrossRef

30.

Radiobiology for the Radiologist. 7th ed. In: Hall EJ, Giaccia AJ, editors. Philadelphia, PA: Lippincott Williams & Wilkins; 2012. p. 41–42.

31.

Brown JM, Carlson DJ, Brenner DJ. Dose escalation, not “new biology”, can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1159–60.PubMedCentralPubMedCrossRef

32.

Song CW, Park I, Cho LC, Yuan J, Dusenbery KE, Griffin RJ, et al. Is indirect cell death involved in response of tumors to stereotactic radiosurgery and stereotactic body radiation therapy? Int J Radiat Oncol Biol Phys. 2014;89(4):924–5.PubMedCrossRef

33.

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9.PubMedCrossRef

34.

Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.PubMedCentralPubMedCrossRef

35.

Lo SS, Teh BS, Wang JZ, Huang Z, Zook J, Price T, et al. Imaging changes after stereotactic body radiation therapy for lung and liver tumors. Expert Rev Anticancer Ther. 2011;11(4):613–20.PubMedCrossRef

36.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradely J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.PubMedCentralPubMedCrossRef

37.

Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.PubMedCrossRef

38.••

Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013;86(2):336–42. Preliminary results from a trial of high-dose radiation for the treatment of liver metastases.PubMedCrossRef

39.

Yaes RJ, Kalend A. Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys. 1998;14(6):1247–59.CrossRef

40.

Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.PubMedCrossRef

41.

Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol. 2001;19(1):164–70.PubMed

42.

Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93.PubMedCrossRef

43.

http://clinicaltrials.gov, Study NCT01233544.

44.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.PubMedCrossRef

45.

Vokes EE, Weichselbaum RR. Concurrent chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990;8(5):911–34.PubMed

46.

Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol. 2007;25(8):947–52.PubMedCrossRef

47.

Yang W, Ahmed M, Elian M, el-SA H, Levchenko TS, Sawant RR, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology. 2010;257(3):685–96.PubMedCentralPubMedCrossRef

48.••

Formenti SC, Demaria S. Radiation therapy to convert the tumor to an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84(4):879–90. An important overview of word studying the interactions of radiation and the immune system.PubMedCrossRef

49.

den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumor immunity. Br J Cancer. 2006;95(7):896–905.CrossRef

50.

Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.PubMedCentralPubMedCrossRef

Titel: Update on Treatment of Liver Metastases: Focus on Ablation Therapies
verfasst von: Jeffrey Meyer
Seth Toomay
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 1/2015
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-014-0420-2

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy

Body Image: a Critical Psychosocial Issue for Patients With Head and Neck Cancer

Defining Value-Driven Care in Head and Neck Oncology